[go: up one dir, main page]

WO2008139496A1 - Insuline humaine de recombinaison et méthode associée - Google Patents

Insuline humaine de recombinaison et méthode associée Download PDF

Info

Publication number
WO2008139496A1
WO2008139496A1 PCT/IN2008/000301 IN2008000301W WO2008139496A1 WO 2008139496 A1 WO2008139496 A1 WO 2008139496A1 IN 2008000301 W IN2008000301 W IN 2008000301W WO 2008139496 A1 WO2008139496 A1 WO 2008139496A1
Authority
WO
WIPO (PCT)
Prior art keywords
human insulin
insulin
recombinant human
precursor
pichia
Prior art date
Application number
PCT/IN2008/000301
Other languages
English (en)
Inventor
Chandrasekhar Bhaskaran Nair
Nirmala Mahesh Nair
Original Assignee
Bigtec Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bigtec Private Limited filed Critical Bigtec Private Limited
Publication of WO2008139496A1 publication Critical patent/WO2008139496A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Definitions

  • the present invention relates to a field of Recombinant DNA therapeutics. It involves the production of recombinant human insulin in pichia pastoris by optimization of codons in pichia expression system and the process parameters. Optimization at multiple steps of the process resulted in increased yield.
  • Human Insulin is currently available in the market from at least three different systems viz. E. coli, Pichia pastoris and Hansenuela polymorpha.
  • E. coli Over expression in E. coli results in proteins accumulating as inclusion bodies in an insoluble form. Solubilization and refolding of the recombinant insulin from the inclusion bodies requires use of chaotropic chemicals such as guanidine hydrochloride, urea, etc. and presence of traces of these chemicals in the final product even after extensive purification could be hazardous.
  • proteins can be expressed in yeast system and secreted out into the medium at much higher levels in soluble form. However, levels of expression obtained in each yeast system differed from protein to protein for reasons still not well understood.
  • the two chains of human insulin are also being expressed separately using two different vectors and assembled together in-vitro after purification. Disulphide linkages between two chains is facilitated by chemical methods
  • Pichia expression system is known for its very high levels of expression. Proteins can be expressed as secretory proteins and therefore purification of the same becomes more easy especially when the cells are grown in minimal mineral media. The doubling time of the strain, ease of handling, minimal growth requirements, availability of convenient vectors, host systems and selection methodologies make Pichia pastoris an ideal and attractive system for study. High cell densities are achievable in minimal mineral media and the ease of induced expression of proteins add to the convenience of using this system for recombinant protein expression.
  • Synthetic Porcine Insulin Precursor (PiP) gene was constructed using eight different oligonucleotides. The gene was cloned into a Pichia Pastoris expression vector and the DNA sequence of the insert and its fusion were confirmed by sequencing. The expression cassette was integrated into the Pichia host system by homologous recombination. Clones harboring high copy number inserts were picked by antibiotic screening. Clones showing maximum resistance to the antibiotic G418 were picked and screened for its performance in terms of its ability to express and secrete the insulin precursor into the culture medium. Promising clones were further evaluated by fermentation at 4L bench scale.
  • the precursor was captured from the broth, purified and enzymatically modified to obtain human insulin with yields up to 1.1 gm/litre which can be further increased through additional optimization of the process.
  • Biological activity of the final product in terms of regulating blood glucose has been established in mice and rats and found to be comparable with that of commercially available therapeutic human insulin.
  • the process has been optimized at multiple steps, which has cumulative effects and resulted in increased yields.
  • the main object of the present invention is to obtain recombinant human insulin comprising the amino acid sequence as set forth in SEQ ID NO: 1.
  • Another main object of the present invention is to obtain recombinant human insulin comprising the amino acid sequence as set forth in SEQID NO: 2.
  • Yet another object of the present invention is to develop a method for obtaining recombinant human insulin comprising the amino acid sequence as set forth in SEQ ID Nos. l and 2.
  • Still another object of the present invention is to produce recombinant human insulin in pichia pastoris for therapeutic use.
  • Still another object of the present invention is to obtain recombinant human insulin by optimization of codons in Pichia expression system.
  • Still another object of the present invention is to obtain recombinant human insulin by optimization of parameters during fermentation of Pichia.
  • Still another object of the present invention is to obtain high fermentation yields.
  • the present invention relate to recombinant human insulin comprising the amino acid sequence as set forth in SEQ ID NO: 1; recombinant human insulin comprising the amino acid sequence as set forth in SEQ ID NO: 2 and a method for obtaining recombinant human insulin comprising the amino acid sequence as set forth in SEQ ID Nos. 1 and 2, said method comprising steps of: a) constructing an insulin precursor gene; b) ligating the precursor gene into a vector; and c) cloning the ligated precursor gene into a host, followed by fermentation to obtain recombinant human insulin.
  • the present invention relates to recombinant human insulin comprising the amino acid sequence as set forth in SEQ ID NO: 1.
  • said SEQ ID No. 1 is obtained by optimization of codons in Pichia species.
  • the present invention also relates to recombinant human insulin comprising the amino acid sequence as set forth in SEQID NO: 2.
  • said SEQ ID No. 2 is obtained by optimization of codons in Pichia species.
  • the present invention also relates to a method for obtaining recombinant human insulin comprising the amino acid sequence as set forth in SEQ ID Nos. 1 and 2, said method comprising steps of: a) constructing an insulin precursor gene; b) ligating the precursor gene into a vector; and c) cloning the ligated precursor gene into a host, followed by fermentation to obtain recombinant human insulin.
  • said insulin precursor is selected from a group comprising porcine insulin precursor and bovine insulin precursor, preferably porcine insulin precursor.
  • said precursor is constructed with about eight oligonucleotides coding for porcine insulin precursor.
  • said vector is selected from a group comprising pPIC9K and pPICZ ⁇ , preferably pPIC9K.
  • said cloning is carried out at downstream of AOXl promoter and Mating Factor Alpha (MFa) signal sequences.
  • said host is selected from a group comprising Pichia pastoris, Pichia methanolica, Pichia guilliermondii and Pichia caribbica, preferably Pichia pastoris.
  • said fermentation is carried out in a suitable medium contained in a modified vessel at a suitable temperature range, aeration, cell densities and feeding.
  • said medium has a pH ranging from about 4.0 - 5.0, preferably about 4.75 during initial phase of fermentation; about 4.0 ,— 5.0, preferably about 4.80 during glycerol phase and about 4.0 - 5.0, preferably about 4.95 during induction phase.
  • said modified vessel comprises methanol probe and sensor to monitor residual methanol and methanol feeding rate; modified air sparger to increase efficiency of aeration and oxygen transfer rate (OTR), aeration delivery pores in sparger are relocated to top side and air bubbles are made to hit impeller directly.
  • OTR aeration and oxygen transfer rate
  • said temperature ranges from about 29 - 31 0 C, preferably about 30.0 0 C for batch phase; about 29 - 3O 0 C, preferably about 29.5 0 C for glycerol fed batch; and about 27-29 0 C, preferably about 28.0 0 C for induction phase with methanol.
  • said aeration ranges from about 0.5 -1.5 VVM pure air, preferably IVVM pure air for batch phase; about 0.5 -1.5 VVM air: oxygen, preferably about 1.0 VVM air: oxygen (about 90:10) for glycerol batch; and about 1.5 VVM air: oxygen ratio begins at about 85:15 and ends at about 40:60 with an increment/decrement of about 5 at about every 5 hours for methanol batch (induction phase).
  • glycerol feeding is carried out to promote high cell density before induction and is continued until cell density (OD ⁇ oo) reaches about 500; methanol is fed exponentially to promote increased expression of target protein.
  • said method is optimized with respect to various parameters selected from a group comprising increasing GC content of coding region, N-terminal spacer sequence, C-peptide region connecting B and A chains of insulin, multiple copy insertions, optimized media components and growth and induction parameters, or a combination thereof.
  • said N-terminal spacer sequence is selected from a group comprising a di-peptide KR and long spacers KREAEA, KREEAEAEAEPK or a combination thereof.
  • said C-peptide region is selected from a group comprising KR and AAK or a combination thereof.
  • incorporation of an aromatic amino acid in C-peptide EWK improves folding stability of insulin precursor.
  • the present invention relates to production of recombinant human insulin in pichia pastoris for therapeutic use.
  • recombinant human insulin is produced by optimization of codons in Pichia expression system. In still another embodiment of the present invention, recombinant human insulin is produced by optimization of parameters during fermentation of Pichia. In still another embodiment of the present invention, fermentation yields are high.
  • Synthetic Porcine Insulin Precursor (PiP) gene was constructed using eight different oligonucleotides. The gene was cloned into a Pichia Pastoris expression vector and the DNA sequence of the insert and its fusion were confirmed by sequencing. The expression cassette was integrated into the Pichia host system by homologous recombination. Clones harboring high copy number inserts were picked by antibiotic screening. Clones showing maximum resistance to the antibiotic G418 were picked and screened for its performance in terms of its ability to express and secrete the insulin precursor into the culture medium. Promising clones were further evaluated by fermentation at 4L bench scale.
  • the precursor was captured from the broth, purified and enzymatically modified to obtain human insulin with yields up to 1.1 gm/litre which can be further increased through additional optimization of the process.
  • Biological activity of the final product in terms of regulating blood glucose has been established in mice and rats and found to be comparable with that of commercially available therapeutic human insulin.
  • the present invention relates to production of recombinant human insulin in Pichia pastoris by optimization of codons in pichia expression system and the process parameters.
  • the parameters optimized include GC content of the coding region, the N- terminal spacer sequence, the C-peptide region connecting the B and A chains, multiple copy insertions, optimized media components. and growth and induction parameters.
  • PIP Porcine Insulin Precursor
  • the N-terminal spacer sequence was kept as short as a di-peptide, KR. While in some, long spacers KREAEA, and KREEAEAEAEPK rich in hydrophilic amino acids were incorporated. A short C-peptide KR or AAK connected B & A chains. Folding stability of the precursor was improved by incorporating an aromatic amino acid in the C-peptide viz. EWK. Comparative analyses were done for these clones both in shake-flasks as well as in fermentor scale. The effects of having a single copy of these genes as in pPICZ ⁇ vector and multiple copies using pPIC9K vectors were compared both in KM71 and GS115 strains of Pichia pastoris .
  • Recombinant pPIC9K plasmid was linearized with Sacl/Bglll, cleaned, estimated and used for transformation into Pichia pastoris. Approximately 20 ⁇ g of the cut DNA were used for each transformation. Spheroplast method of transformation was preferred over the lithium chloride method in order to obtain multiple insertions. Expression cassette was inserted into the host genome by homologous recombination thereby stably maintaining the insert in the clones. Copy numbers of the gene in each transformant depends upon the number of insertions that had taken place during the transformation. The transformants were plated on minimal media lacking histidine and the His "1" colonies that grew on these plates were picked and grown on fresh plates for further screening of the colonies.
  • Clones containing multiple copies of the gene inserted into the genome were screened using antibiotic G418. Colonies resistant to more than 6mg G418 are considered to -> contain more than twelve copies of the gene. Such colonies were selected, grown and maintained at -7O 0 C as glycerol stock.
  • Example 2 Shake flask experiments Transformed colonies after G418 selection are plated onto YPD plates. These colonies were then screened for expression cloned gene by shake flask cultures according to the Invitrogen's Pichia Expression Kit. More than 3000 such colonies were screened to identify few promising clones.
  • Each colony to be screened was grown in 5 ml YPD in a culture tube by incubating at 3O 0 C / 230rpm / 24hrs.
  • the seed is transferred to 20 ml YPD in 100ml Erlenmeyer flask and incubated at 3O 0 C / 230rpm / 24hrs.
  • Cells were harvested by centrifuging at 8000rpm for 10 minutes at room temperature. Supernatant was decanted and the cell pellet was resuspended in 75ml BMG (buffered minimum glycerol medium) to a final ODeoo nm of 2.0. Cells were then allowed to grow at 3O 0 C / 230rpm.
  • the culture was induced with 1.0% methanol at every 24hrs to maintain a fed-batch induction for 72hrs. Growth and induction was monitored every 24hrs. Total protein content in the supernatant was quantified by Bradford colorimetric method, RP-HPLC and/or by gel electrophoresis (SDS-PAGE).
  • Colonies showing good expression were then picked, streaked and stored separately for further evaluation at fermentation scales.
  • Fermentation was carried in in-situ autoclavable automated vessel (BioFlow 415, NBS) of 7 litre capacity.
  • the vessel is controlled by touch screen monitor for calibration and adjusting all parameters like agitation, gas flow rates, feeding, pH adjustments, antifoam.
  • the fermentation process is optimized by making some changes in the vessel like modification of air sprger, modification of impeller, attachment of methanol probe along with methanol sensor to the vessel.
  • the fermentation medium used is Basal Salt Medium (BSM) supplemented with tracemetal salts solution (6%) and biotin.
  • BSM Basal Salt Medium
  • tracemetal salts solution 6%) and biotin.
  • glycerol stock is inoculated and grown in YPD medium by shake flask culture for 18 - 20 hrs at 220 rpm/30°C till OD 60O reaches 10-12.
  • the first seed is again inoculated onto YPG medium and grown at above mentioned conditions.
  • Batch phase The fermenter medium pH adjusted to 4.75 before inoculation to avoid precipitation of medium if any.
  • Dissolved oxygen (DO) probe is also calibrated before inoculation. Trace metal solution of 8% added to the vessel before and after inoculation at fixed intervals. Temperature of the culture is maintained at 3O 0 C. Vessel aeration was maintained as 1.0 VVM pure air. Initial batch phase last for 18 hrs until ODeoo reaches 120-150 with an indication of DO shoot up.
  • DO Dissolved oxygen
  • Glycerol fed batch The glycerol fed batch started with feeding of 50% glycerol containing 12% trace metal solution on exponential feed rate to achieve high cell density before induction. Temperature and pH were maintained at 29.5 0 C and 4.80. Vessel aeration was maintained as 1.0 VVM air and oxygen in a ratio of 9:1. Glycerol batch last for 4 - 6 hours until OD 6 oo reaches 500.
  • Methanol batch Induction of PIP was started by feeding 100% methanol containing 12% trace metal solution. Initial methanol feed was given as spikes until culture gets adapted, subsequently switched on to exponential feed. The DO spike method was used to determine ramp of methanol feed. Methanol feed for Mut + and Mut s clones were based on Stratton et al., (Pichia protocols, Methods in Molecular Biology, Vol.103). Residual methanol in the vessel is continuously monitored using an in-house designed methanol probe and methanol sensor connected to the vessel. Consumption of methanol signals increase in vessel temperature which is maintained at 28.5 0 C through out methanol fed batch. PH was maintained at 4.95.
  • Vessel aeration was maintained as 1.5 VVM due to high density with air and oxygen in a ratio begins at 85:15 and ends at 40:60 with an increment/decrement of 5 at every 5 hrs.
  • induction phase samples were analyzed at 6-hours interval to check growth, induction and contamination if any.
  • Induced protein secreted into broth which is analyzed by HPLC using acetonitrile / ammonium sulphate solvents in Cl 8 column. Samples were also analyzed by SDS- PAGE to assess the expression of PIP and content of host proteins. Induction was carried for 48-50 hrs until cell OD ⁇ oo reaches 1200 - 1500. Then the batch is terminated and cells are harvested by centrifugation. The cell free broth is clarified by filtration through 0.22 ⁇ membrane to remove suspended particles and then used for purification of secreted PIP.
  • the clarified broth from fermentation batch contain high molecular weight host proteins and PIP bound pigment.
  • the broth is diluted thrice with MiIIiQ water and passed through Millipore TFF system (Pellicon) fixed with lOkda , 0.1m 2 NMWC membrane using peristaltic pump.
  • the protein in the broth is concentrated from 1.5 mg/mL to 7.5mg/mL.
  • the retentate and permeate were checked by HPLC as well as SDS-PAGE.
  • the lOkda permeate is showing traces of PIP which was again concentrated using 3kda membrane.
  • the retentate of 3kda showing around 4-5mg/mL PIP with elimination of most of the host proteins.
  • the retentate of lOkda is further involved in purification of PIP, where as the retentate of 3kda is lyophilized and used for trypsin digestion and transeptidation.
  • PIP Purification of PIP: The PIP in 3kda and lOkda retentates is subjected to ion exchange chromatography using CM Sepharose (Fast Flow) in acetate buffer pH 4.5 using gradient with 0.5 M NaCl. The fractions containing PIP are pooled, dialyzed to remove salt and then lyophilized. Thus pure PIP is sequestered from high molecular weight impurities and pigment. The PIP in lyophilized form is >95% pure and showed rhombohedral crystals. Conversion of PIP to human Insulin: Human insulin from Purified, lyophilized PIP was obtained by a combined reaction called trypsin digestion and transpeptidation.
  • the lyophilized PIP was dissolved in Tris buffer and treated with TPCK treated trypsin (without chymotrypsin activity) at 37 0 C for 1 hr.
  • the reaction was stopped by lowering the pH.
  • Crude digestion mixture forms an intermediate namely DES B30 which is mostly converted into methylated human insulin (HIOMe) in presence of threonine methyl ester (TME) by a coupling reaction in presence of Tris buffered DMSO : 1,4 Butanediol (1:2).
  • TME threonine methyl ester
  • the reaction mixture is then precipitated using ten volumes of ice- cold acetone acidified with 0.1% HCl.
  • the precipitate collected by centrifugation was washed once with acetone, dried and dissolved in 1.0M acetic acid. Trypsin and TME in the mixture were removed by Sephadex G-50 gel filtration in an acidic medium. The fraction corresponding to HIOMe was collected, diluted
  • Human Insulin was obtained from HIOMe by deblocking at 25 0 C and pH 10.5. The conversion was confirmed by HPLC and the product was purified by preparative FPLC using acetonitrile : ammonium sulphate buffer mixture. Peak corresponding to HI was collected, acetonitrile was removed by rotavapor at 4O 0 C and then lyophilized. The resultant powder was re-dissolved in 1.0 M acetic acid and subjected to gel filtration to remove the residual buffer. Finally, acetic acid was removed by lyophilization and human insulin (HI) was obtained by crystallization.
  • HI thus obtained in our lab was reconstituted in saline and m-cresol to a concentration of 6.62mg/ml based on the HPLC peak area in comparison with the commercial human insulin. This sample was administered to experimentally induced diabetic mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention porte sur la production d'insuline humaine de recombinaison dans le Pichia pastoris par optimisation de codons dans le système d'expression du Pichia et des paramètres de processus. Les paramètres optimisés incluent: le contenu GC de la région de codage, la séquence d'espaceur N-terminale, la région du peptide C reliant les chaînes A et B, des insertions de copies multiples, des composants de milieu optimisés, et des paramètres d'induction et de croissance. Le processus optimisé en plusieurs étapes à des effets cumulatifs se traduisant par un accroissement du rendement.
PCT/IN2008/000301 2007-05-16 2008-05-14 Insuline humaine de recombinaison et méthode associée WO2008139496A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1037CH2007 2007-05-16
IN01037/CHE/2007 2007-05-16

Publications (1)

Publication Number Publication Date
WO2008139496A1 true WO2008139496A1 (fr) 2008-11-20

Family

ID=40001741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000301 WO2008139496A1 (fr) 2007-05-16 2008-05-14 Insuline humaine de recombinaison et méthode associée

Country Status (1)

Country Link
WO (1) WO2008139496A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057318A1 (en) * 2009-03-12 2014-02-27 Bigtec Private Limited Polynucleotide and polypeptide sequence and methods thereof
US10378005B2 (en) 2009-12-24 2019-08-13 University Court Of The University Of Edinburgh Recombinant factor H and variants and conjugates thereof
CN116355101A (zh) * 2023-03-09 2023-06-30 北京惠之衡生物科技有限公司 一种门冬胰岛素的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214826A2 (fr) * 1985-08-30 1987-03-18 Novo Nordisk A/S Analogues d'insuline et leur méthode de préparation
WO1997003089A2 (fr) * 1995-07-08 1997-01-30 University Of Leicester Procede de preparation d'insuline par clivage d'une proteine de fusion et proteines de fusion contenant des chaines a et b d'insuline
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US20030104607A1 (en) * 2000-09-13 2003-06-05 Nestor Annibali Expression of a human insulin precursor in P. pastoris

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214826A2 (fr) * 1985-08-30 1987-03-18 Novo Nordisk A/S Analogues d'insuline et leur méthode de préparation
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
WO1997003089A2 (fr) * 1995-07-08 1997-01-30 University Of Leicester Procede de preparation d'insuline par clivage d'une proteine de fusion et proteines de fusion contenant des chaines a et b d'insuline
US20030104607A1 (en) * 2000-09-13 2003-06-05 Nestor Annibali Expression of a human insulin precursor in P. pastoris

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARKUSSEN J. ET AL.: "Soloble, prolonged-acting insulin derivatives. II. Degree of protraction and cyrstallization of insulins substituted in positions A17, B8, B13, B27 and B30", PROTEIN ENGINEERING, vol. 1, no. 3, 1987, pages 215 - 223, XP001018792 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057318A1 (en) * 2009-03-12 2014-02-27 Bigtec Private Limited Polynucleotide and polypeptide sequence and methods thereof
US9238674B2 (en) 2009-03-12 2016-01-19 Bigtec Private Limited Polynucleotide and polypeptide sequence and methods thereof
US9309281B2 (en) * 2009-03-12 2016-04-12 Bigtec Private Limited Method of downstream processing for conversion of human insulin precursor molecule into a functional human insulin protein molecule
US10378005B2 (en) 2009-12-24 2019-08-13 University Court Of The University Of Edinburgh Recombinant factor H and variants and conjugates thereof
CN116355101A (zh) * 2023-03-09 2023-06-30 北京惠之衡生物科技有限公司 一种门冬胰岛素的制备方法
CN116355101B (zh) * 2023-03-09 2024-05-03 北京惠之衡生物科技有限公司 一种门冬胰岛素的制备方法

Similar Documents

Publication Publication Date Title
EP2406377B1 (fr) Séquence polynucléotidique et polypeptidique et ses procédés
JP2662390B2 (ja) インシユリン類似体
RU2495131C2 (ru) Способ получения рекомбинантного инсулина гларгина
EP2534255B1 (fr) Méthode de diminution de la glycosylation de protéines, procédés et protéines
US20220290202A1 (en) Aminoacyl-trna synthetase efficiently introducing lysine derivatives
WO2017126984A1 (fr) Procédé de production d'insuline et de dérivés d'insuline et peptide hybride utilisé dans ce procédé
WO2020187271A1 (fr) Introduction d'acides aminés non naturels dans des protéines à l'aide d'un système plasmidique double
CA3155547A1 (fr) Acides nucleiques, vecteurs, cellules hotes et procedes de production de beeta-fructofuranosidase a partir d'aspergillus niger
WO2008139496A1 (fr) Insuline humaine de recombinaison et méthode associée
AU2019218315A1 (en) Codon optimized precursor gene and signal peptide gene of human insulin analogue
CZ20021227A3 (cs) Monomerní analogy lidského inzulínu
US20070128622A1 (en) Chimeric Human Growth Hormone Derived From The Placenta And Pituitary Isoform And Processes For Obtaining Said Chimera
WO2021048878A1 (fr) Séquences d'extension n-terminale pour l'expression de peptides thérapeutiques recombinants
CN1049249C (zh) 胰岛素前体基因在酵母中的分泌表达和人胰岛素的制备
RU2104305C1 (ru) Аналоги инсулина человека, способ их получения, раствор для инъекций
US20090035815A1 (en) Synthetic Gene for Enhanced Expression in E. Coli
ZA200606318B (en) Chimeric human growth hormone derived from the placenta and pituitary isoform and processes for obtaining said chimera
KR20070035483A (ko) 태반 및 뇌하수체 아형 유래의 키메라 인간 성장 호르몬 및상기 키메라의 제조 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08776664

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08776664

Country of ref document: EP

Kind code of ref document: A1